\
&
Contact us
\
&
Contact us
Published on | 2 hours ago
Programmes HealthThe European Partnership ofor Personalised Medicine (EP PerMed) is about to launch an international call titled 'Personalised Medicine for cardiovascular, metabolic, and kidney diseases' (CARMEN2026) to fund multinational, innovative research projects in personalised medicine.
The aim of this Call, foreseen to be launched on 25 November 2025, is to fund research projects in human health on innovative personalised medicine strategies for patients with cardiovascular, metabolic or kidney diseases. Research projects may focus on a single disease or explore these conditions in combination.
Proposals should address one or more of the following aspects:
Research Foundation Flanders (FWO) plans to participate in this call. More information on available funding for researchers based in Flanders and on how to apply will be published on FWO's website soon. Deadline for the submission of pre-proposals is 10 February 2026. Questions on available funding by FWO? Contact europe@fwo.be.
More information on the call, its conditions and how to apply will be made available soon on the EP PerMed dedicated webpage. Interested in applying? Join the information webinar on 16 December 2025 here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
